Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
Flash
16:58
In the past 24 hours, the MarketVectorTM Digital Assets 100 Small Cap Index dropped 0.87%, currently standing at 2285.71 points. During a V-shaped rebound, the index hit its period low of 2260.26 at 07:37 (GMT+8), and in a round of spike and retracement, reached a period high of 2331.37 at 21:50.
MarketVectorTM Digital Assets 100 Mid-Cap Index rose by 0.43% to 2,662.57 points. During the period, it reached a low of 2,598.96 points at 07:36 (UTC+8) and a high of 2,699.43 points at 21:50 (UTC+8). The MarketVector Digital Assets 100 Index increased by 0.71% to 12,806.37 points. Currently, Solana is down by 1.93%, Dogecoin is down by 0.28%, and XRP is down by 0.67%. Bitcoin is up by 0.86%, currently at $64,687.74; Ethereum is up by 0.31%, currently at $1,738.19.
16:54
LME copper futures closed up by $54, at $13,649 per ton.
LME aluminum futures closed down by 32 USD, at 3,364 USD/ton. LME zinc futures closed up by 52 USD, at 3,608 USD/ton.
16:52
Arrowhead Pharmaceuticals announced that its drug Redemplo® (Plozasiran) has received marketing authorization from the European Commission for lowering triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).
FCS is a rare and severe genetic disease characterized by extremely high levels of triglycerides in the blood, which can lead to life-threatening pancreatitis. This approval marks a significant advancement for Arrowhead Pharmaceuticals in the field of rare disease treatments, providing a new treatment option for FCS patients in Europe. The company stated that it is committed to bringing this innovative therapy to patients in need as soon as possible.
Markets